The MSA treatment landscape is evolving with increased research into disease-modifying therapies targeting underlying pathology. Rising diagnostic rates and orphan drug development incentives are accelerating market growth. Biotechnology leaders including Biohaven Pharmaceuticals, Theravance Biopharma, and Modag GmbH are advancing innovative candidates addressing α-synuclein aggregation and neuroprotection in clinical trials. Access Detailed Market Forecast: https://www.delveinsight.com/infographics/multiple-system-atrophy-msa-market?utm_source=infographics&utm_medium=promotion&utm_campaign=kkpr